NO20055652L - Laktatinneholdende farmasoytisk preparat og anvendelse av dette - Google Patents

Laktatinneholdende farmasoytisk preparat og anvendelse av dette

Info

Publication number
NO20055652L
NO20055652L NO20055652A NO20055652A NO20055652L NO 20055652 L NO20055652 L NO 20055652L NO 20055652 A NO20055652 A NO 20055652A NO 20055652 A NO20055652 A NO 20055652A NO 20055652 L NO20055652 L NO 20055652L
Authority
NO
Norway
Prior art keywords
lactate
millimoles per
pharmaceutical preparation
liters
containing pharmaceutical
Prior art date
Application number
NO20055652A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055652D0 (no
Inventor
Xavier M Leverve
Mustafa Iqbal
Original Assignee
Innogene Kalbiotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd
Publication of NO20055652D0 publication Critical patent/NO20055652D0/no
Publication of NO20055652L publication Critical patent/NO20055652L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
NO20055652A 2003-05-01 2005-11-30 Laktatinneholdende farmasoytisk preparat og anvendelse av dette NO20055652L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01
PCT/SG2004/000066 WO2004096204A1 (en) 2003-05-01 2004-03-22 Lactate containing pharmaceutical composition and uses thereof

Publications (2)

Publication Number Publication Date
NO20055652D0 NO20055652D0 (no) 2005-11-30
NO20055652L true NO20055652L (no) 2006-02-01

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055652A NO20055652L (no) 2003-05-01 2005-11-30 Laktatinneholdende farmasoytisk preparat og anvendelse av dette

Country Status (30)

Country Link
US (1) US20080125488A1 (pl)
EP (2) EP1617834B1 (pl)
JP (1) JP5037937B2 (pl)
KR (1) KR101076059B1 (pl)
CN (1) CN1777416B (pl)
AR (1) AR043670A1 (pl)
AT (1) ATE340568T1 (pl)
AU (1) AU2004233904B2 (pl)
BR (1) BRPI0409867A (pl)
CA (1) CA2523740C (pl)
CY (1) CY1105880T1 (pl)
DE (1) DE602004002585T2 (pl)
DK (1) DK1617834T3 (pl)
EA (2) EA013846B1 (pl)
ES (1) ES2274438T3 (pl)
IL (1) IL171721A (pl)
MA (1) MA27845A1 (pl)
MX (1) MXPA05011532A (pl)
MY (1) MY140382A (pl)
NO (1) NO20055652L (pl)
NZ (1) NZ543201A (pl)
PL (1) PL1617834T3 (pl)
PT (1) PT1617834E (pl)
SG (1) SG160217A1 (pl)
SI (1) SI1617834T1 (pl)
TN (1) TNSN05275A1 (pl)
TW (1) TWI290045B (pl)
UA (1) UA86937C2 (pl)
WO (1) WO2004096204A1 (pl)
ZA (1) ZA200509684B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007371A4 (en) * 2006-04-03 2009-07-22 Innogene Kalbiotech Pte Ltd LACTAT AND CALCIUM-CONTAINED PHARMACEUTICAL COMPOSITION AND ITS USES
PL2142186T3 (pl) 2007-03-30 2014-09-30 Laccure Ab Stosowanie oligomerów kwasu mlekowego w leczeniu zaburzeń ginekologicznych
WO2010111650A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
AU2010229668C1 (en) 2009-03-26 2016-09-15 Pulmatrix Operating Co., Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
WO2012044736A1 (en) 2010-09-29 2012-04-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
US10660869B2 (en) * 2012-08-01 2020-05-26 Purac Biochem B.V. Lactate powder and method for the preparation thereof
US9500657B2 (en) 2012-10-25 2016-11-22 Run Them Sweet Llc Formulations containing labels for medical diagnostics
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
EP2754356A1 (en) 2013-01-15 2014-07-16 Purac Biochem N.V. Improved nisin production process
EP2769630B1 (en) 2013-02-26 2016-04-27 Purac Biochem N.V. Improved nisin production process
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
CN112402434A (zh) 2013-11-06 2021-02-26 埃罗米克斯公司 新配方
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
CA3026631C (en) 2016-07-07 2024-03-26 Dsm Ip Assets B.V. Process for obtaining a rapeseed protein isolate and protein isolate thereby obtained
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
US20200246127A1 (en) * 2019-02-06 2020-08-06 Lumen Therapeutics, Llc Biologically modified vascular grafts for improved bypass surgery outcomes
EP4093507A4 (en) * 2020-01-24 2024-02-28 Barkey, Daniel, Q. COMPOSITIONS AND METHODS FOR WEIGHT LOSS
US20250041214A1 (en) * 2021-12-16 2025-02-06 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease
CN116531358A (zh) * 2023-06-06 2023-08-04 中国医科大学附属第一医院 含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用
EP4502147A1 (en) 2023-07-31 2025-02-05 M2Rlab SL Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6776887A (en) * 1985-12-18 1987-07-15 Veech, R.L. Fluid therapy with l-lactate and/or pyruvate anions
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
DK0701455T3 (da) * 1993-06-04 2001-06-18 Biotime Inc Plasmalignende opløsning
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
EA013846B1 (ru) 2010-08-30
WO2004096204A1 (en) 2004-11-11
PT1617834E (pt) 2007-01-31
ZA200509684B (en) 2007-03-28
ES2274438T3 (es) 2007-05-16
SG160217A1 (en) 2010-04-29
JP2006525324A (ja) 2006-11-09
JP5037937B2 (ja) 2012-10-03
KR20050119701A (ko) 2005-12-21
ATE340568T1 (de) 2006-10-15
EP1617834B1 (en) 2006-09-27
MY140382A (en) 2009-12-31
CA2523740A1 (en) 2004-11-11
IL171721A (en) 2012-05-31
DE602004002585D1 (de) 2006-11-09
KR101076059B1 (ko) 2011-10-21
CY1105880T1 (el) 2011-02-02
EA200501675A1 (ru) 2006-06-30
CN1777416A (zh) 2006-05-24
TW200423923A (en) 2004-11-16
UA86937C2 (ru) 2009-06-10
EP1759695A1 (en) 2007-03-07
AR043670A1 (es) 2005-08-03
EA200801073A1 (ru) 2008-08-29
BRPI0409867A (pt) 2006-05-16
EA010948B1 (ru) 2008-12-30
MA27845A1 (fr) 2006-04-03
HK1085942A1 (en) 2006-09-08
AU2004233904A1 (en) 2004-11-11
DE602004002585T2 (de) 2007-10-25
EP1617834A1 (en) 2006-01-25
SI1617834T1 (sl) 2007-02-28
NO20055652D0 (no) 2005-11-30
TWI290045B (en) 2007-11-21
TNSN05275A1 (en) 2007-07-10
AU2004233904B2 (en) 2009-11-12
PL1617834T3 (pl) 2007-02-28
NZ543201A (en) 2007-05-31
CN1777416B (zh) 2012-11-07
CA2523740C (en) 2012-05-15
DK1617834T3 (da) 2007-02-05
MXPA05011532A (es) 2006-05-31
US20080125488A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
NO20055652L (no) Laktatinneholdende farmasoytisk preparat og anvendelse av dette
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
AU2003275958A1 (en) Muteins of tear lipocalin
BRPI0510619A (pt) preparação e cápsula contendo a mesma
MX2009002220A (es) Sistemas y metodos desinfectantes.
HUP0401144A2 (hu) Enterális tápszerkészítmények
HUP0401140A2 (en) Disinfectant solution based on sodium hypochlorite, and process for preparing it
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE408022T1 (de) Ermittlung des patientenbezogenen kariesrisikos
ATE494894T1 (de) Viruzide wirkungen von einer zubereitung enthaltend cetylpyridiniumchlorid und zitronensäure
DE60326263D1 (de) Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten
AU2003273728A1 (en) A new crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid
NO20040821L (no) 3-substituerte 6,7-dihydroksytetrahydroisokinolinderivater for andvendelse som antibakterielle midler.
WO2003086335A8 (en) Hair care composition for restoring the elasticity of hair
DK1409449T3 (da) Alpha-ketoglutarater af aktive ingredienser og sammensætninger omfattende disse
HUP0301864A2 (hu) Fenoláttartalmú, alacsony fagyáspontú készítmény
CN105792809A (zh) 口腔用组合物
DE50312414D1 (de) Kompositmaterialien aus calciumverbindungen und glucuronsäurehaltigen polysacchariden
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
MY164917A (en) Lactate containing pharmaceutical composition and uses thereof
ATE476195T1 (de) Zubereitungen von pro-insulin-c-peptid mit verzögerter freisetzung
NO20004708L (no) Anvendelse av naturlig og/eller syntetisk kininsyre og/eller forlöpere derav som anti-insektsmiddel
MXPA05008860A (es) Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas.
ATE390934T1 (de) Aspirin enthaltende transdermale pharmazeutische zusammensetzung zur behandlung von verkalkung
TH104292A (th) องค์ประกอบของผลิตภัณฑ์ยาที่มีแลคเตตและแคลเซียมและการใช้องค์ประกอบดังกล่าว

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application